Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition to its narcolepsy therapy Provigil. In a statement ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

However Cephalon did not see a need for, or decide to ever use, the licence. Teva said in a statement: “The Commission started investigating this agreement in December 2009.

Cephalon and Ception Therapeutics have entered into an agreement that provides Cephalon with an option to purchase all outstanding capital stock of Ception. Ception's lead drug is reslizumab ...